the name 25d-nbome, which short-hand for 2c-d-nbome, is a derivative of the phenethylamine psychedelic 2c-d. it was first synthesized in 2011 by martin hansen and subsequently had its activity explored in 2012 and 2014, where it was established to be a potent agonist at the 5-ht2a receptor that produces effects similar to other members of the 25x-nbome series.
it is worth noting that compounds of the nbome family are not orally active and should be administered sublingually by placing and letting it absorb into one’s mouth over a period of 15-25 minutes. 25d-nbome can also be vaporized and inhaled to cause significantly more rapid and powerful effects as well as a shorter duration. however, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range as well as having a low therapeutic index.
25d-nbome has no history of human use prior to being sold online as a designer drug in 2010. extremely little is known about the pharmacological properties, metabolism, and toxicity of 25d-nbome in humans, and its closely related analogs like 25i-nbome has been associated with many deaths and hospitalizations. along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices when using it.
25d-nbome, or 2c-d-nbome, is a serotonergic n-benzyl derivative of the substituted phenethylamine psychedelic known as 2c-d. 25d-nbome is a substituted phenethylamine with methoxy groups ch3o- attached to carbons r2 and r5 as well as a methyl group attached to carbon r4. it differs from 2c-d structurally through a substitution on the amine (nh2) with a 2-methoxybenzyl (bome) group as shown in the image to the right. 25d-nbome shares this 2-methoxybenzyl substitution with other chemicals of the nbome family. this nbome addition contains a methoxy ether ch3o- bound to a benzene ring at r2.
25d-nbome has efficacy at the 5-ht2a receptor where it acts as a partial agonist. however, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. the addition of the nbome group to the structure results in a sixteen-fold increase in potency when compared to 2c-d, allowing even the most extreme of doses to fit in liquid form onto tabs and blotter paper, which people often mistake for lsd.